Schizophrenia, Bipolar Disorder, and the Psychosis Continuum
Awareness of differences between psychosis in schizophrenia and bipolar disorder and varying presentations in patients can assist providers with diagnosis and treatment.
Schizophrenia and Psychoses
SCHIZOPHRENIA AND PSYCHOSES
Featured Article
Latest News
Antipsychotic Use Safer Than No Use in Schizophrenia
Among patients with schizophrenia, long-term antipsychotic use does not appear to increase severe physical morbidity or somatic hospitalization, and mortality is lower for antipsychotic use compared with no use.
Is There Genetic Overlap Between BMI and Major Psychiatric Disorders?
The findings suggest that factors such as antipsychotic treatment, diet, or lifestyle may contribute to weight gain in patients with long-term disease.
Lumateperone Shows Promise as Treatment for Schizophrenia
Current antipsychotic therapy, effective primarily for positive symptoms but limited with negative symptoms, may be related to serious adverse effects, including motor impairments, prolactin abnormalities, and cardiometabolic disturbances.
Immune-HPA Axis Dysregulation and Stress Linked to Postpartum Psychosis
The researchers noted that recent stressful life events, perceived stress, daily cortisol levels, and high sensitivity C-reactive protein levels accounted for 78% of the variance between women with postpartum psychosis and healthy controls and 46% of the variance between at-risk women and healthy controls.
Olanzapine, Clozapine Show Worst Metabolic Effects Among Antipsychotics
Symptom reduction was significantly correlated with poor metabolic adverse effects, including weight gain, elevated BMI, and higher total cholesterol.
Study Recommends Revised CAPE-P15 Cutoff Values for Detecting Psychotic Experiences
The investigators recommended revising the CAPE-P15 cutoff thresholds to 1.30 and 1.29 for the frequency and distress subscales, respectively. These cutoff values have high sensitivity for psychotic experiences.
No Evidence of a Common Genetic Link Between Schizophrenia and Cannabis Use Disorder
Researchers conducted a case-control study to examine the associations between polygenic risk scores for schizophrenia and other mental disorders with the development of cannabis use disorder.
FDA Approves Caplyta for Schizophrenia
The Food and Drug Administration (FDA) has approved Caplyta (lumateperone; Intra-Cellular Therapies), an atypical antipsychotic, for the treatment of schizophrenia in adult patients.
White Matter Microstructure in Schizophrenia Not Related to Polygenic Risk Score
Investigators assessed the influence of polygenic risk score on white matter microstructure, which is known to be impaired in individuals with schizophrenia, bipolar disorder, and their relatives.
Dopamine-Related Disruption of Auditory Input to Salience Network Involved in Psychosis
Theories of schizophrenia pathophysiology have linked dopamine function with positive symptoms, as well as disrupted salience processing.
Want to read more?
Please login or register first to view this content.
Next post in Schizophrenia and Psychoses
